Multiple Sclerosis Trials in North Carolina

A listing of Multiple Sclerosis Trials in North Carolina actively recruiting patient volunteers.

Search by Name
Filter by Condition
Multiple Sclerosis
6 trials found

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis


This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046) are eligible for enrollment in this extension study. Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at ...

Conditions: Multiple Sclerosis

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy


This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no disease modifying therapies (DMTs). The data of this study will support the labels for ozanimod in multiple sclerosis (MS) because the effect of ozanimod on the vaccination response of MS participants is of interest to participants and prescribers.

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders


This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result >200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 va ...

Conditions: Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Systemic Sclerosis (SSc), Pediatric SLE, Pediatric-Onset Multiple Sclerosis (POMS), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM)

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)


This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks in participants with PPMS, in comparison to the approved 600 mg dose of ocrelizumab.

Conditions: Multiple Sclerosis

OCTA in Mild Cognitive Impairment and Alzheimer's Disease


This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography angiography (OCTA) to assess the structure and function of the retinal microvasculature in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD) or other neurodegenerative disease, multiple sclerosis, and Huntington's disease.

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Retinal Vascular, Parkinson Disease, Multiple Sclerosis, Huntington Disease, Neuro-Degenerative Disease
Phase: Not Applicable

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis


To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)

Conditions: Multiple Sclerosis